drugset / Trial / NCT05365321
Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 1, multi-center, dose escalation study that is followed by a Phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of WP1122 administered q12h ±1 hr PO in adult patients with COVID-19 who require hospitalization with respiratory support. The Phase 1 component will enroll COVID-19 positive patients who are symptomatic and the Phase 2 component will enroll adults with COVID-19 who require hospitalization for respiratory support and those patients requiring intubation with mechanical ventilation.
Timeline
- Start
- 2022-12
- Primary completion
- 2023-02
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WP1122 | Small molecule | 8 mg/kg | Oral |
| Subject | WP1122 | Small molecule | 16 mg/kg | Oral |
| Subject | WP1122 | Small molecule | 32 mg/kg | Oral |
| Subject | WP1122 | Small molecule | 64 mg/kg | Oral |